Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.

Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this ...

The Food and Drug Administration has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication, according to a press release from the ...

Dupixent, an interleukin-4 receptor alpha antagonist, is the first treatment indicated for prurigo nodularis. Credit: Getty Images. The Food and Drug Administration (FDA) has approved Dupixent ® ...

Please provide your email address to receive an email when new articles are posted on . By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of ...

The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals. Prurigo nodularis, a chronic, ...

Prurigo nodularis (PN) is a skin condition marked by extremely itchy bumps that form due to repeated scratching, picking, or rubbing. The itch-scratch cycle — where itching prompts scratching, which ...

Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S. TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, ...

Please provide your email address to receive an email when new articles are posted on . Prurigo nodularis, a chronic debilitating inflammatory skin disease that causes extreme quality of life ...